Cargando…
Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting
AIMS: To determine potentially significant drug interactions in an old age setting among inpatients with psychosis and medical comorbidities over the past 12 months METHODS: Study setting: old age inpatient functional ward Sample size: 11 Inpatients on psychotropic medications with diagnosis ranging...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345774/ http://dx.doi.org/10.1192/bjo.2023.496 |
_version_ | 1785073167021113344 |
---|---|
author | Tewari, Abhinav Pathak, Ashish |
author_facet | Tewari, Abhinav Pathak, Ashish |
author_sort | Tewari, Abhinav |
collection | PubMed |
description | AIMS: To determine potentially significant drug interactions in an old age setting among inpatients with psychosis and medical comorbidities over the past 12 months METHODS: Study setting: old age inpatient functional ward Sample size: 11 Inpatients on psychotropic medications with diagnosis ranging from F20 to F29 (ICD-10). Comorbid chronic medical condition(s) requiring long term drug treatment. Patients with other/co-existing mental health diagnosis excluded. Antibiotics , OTC medications, herbal treatments, emergency treatments and other medications requiring short-term administration excluded from analysis. : Category X: Avoid combination. Category D: Consider therapy modification. Further categories (In order of decreasing risk ratings: C, B, A) excluded from the analysis. RESULTS: Out of the total 67 inpatients admitted between January 2022 and December 2022, 17 patients had diagnosis ranging between F20 and F29. 4 patients were excluded due to no medical comorbidities and 2 were excluded due to lack of data. Among the 11 patients included in the analysis, the most common medical comorbidities were, in decreasing order, hypertension, hypercholesterolemia and chronic pain. A total of 114 interactions were noted between psychotropic medications and other physical health medications, as follows: No significant interactions: (category A, B, C): 103 : 7 of these interactions were associated with administering Buprenorphine with other medications (Flupentixol, Gabapentin, Nortriptyline, Olanzapine, Amisulpride, Aripiprazole and Pregabalin) leading to additive CNS depressant effects. Interaction of codeine with Valproate and Flupentixol carried risk of CNS depression. Carbamazepine interacted with Risperidone via CYP enzyme induction. : The interaction between Flupentixol and Glycopyrronium was associated with risk of severe anticholinergic effects. CONCLUSION: This study is a preliminary investigation towards understanding the drug interactions in a population with long term mental health and physical health ailments. Awareness regarding the potential interactions can help avoid combinations with possible detrimental effects. The limitations of this study, in terms of sample size and quality of available data, can be overcome by conducting a planned study on a larger population. Financial Sponsorship: none Conflict of interests: none |
format | Online Article Text |
id | pubmed-10345774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103457742023-07-15 Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting Tewari, Abhinav Pathak, Ashish BJPsych Open Psychopharmacology AIMS: To determine potentially significant drug interactions in an old age setting among inpatients with psychosis and medical comorbidities over the past 12 months METHODS: Study setting: old age inpatient functional ward Sample size: 11 Inpatients on psychotropic medications with diagnosis ranging from F20 to F29 (ICD-10). Comorbid chronic medical condition(s) requiring long term drug treatment. Patients with other/co-existing mental health diagnosis excluded. Antibiotics , OTC medications, herbal treatments, emergency treatments and other medications requiring short-term administration excluded from analysis. : Category X: Avoid combination. Category D: Consider therapy modification. Further categories (In order of decreasing risk ratings: C, B, A) excluded from the analysis. RESULTS: Out of the total 67 inpatients admitted between January 2022 and December 2022, 17 patients had diagnosis ranging between F20 and F29. 4 patients were excluded due to no medical comorbidities and 2 were excluded due to lack of data. Among the 11 patients included in the analysis, the most common medical comorbidities were, in decreasing order, hypertension, hypercholesterolemia and chronic pain. A total of 114 interactions were noted between psychotropic medications and other physical health medications, as follows: No significant interactions: (category A, B, C): 103 : 7 of these interactions were associated with administering Buprenorphine with other medications (Flupentixol, Gabapentin, Nortriptyline, Olanzapine, Amisulpride, Aripiprazole and Pregabalin) leading to additive CNS depressant effects. Interaction of codeine with Valproate and Flupentixol carried risk of CNS depression. Carbamazepine interacted with Risperidone via CYP enzyme induction. : The interaction between Flupentixol and Glycopyrronium was associated with risk of severe anticholinergic effects. CONCLUSION: This study is a preliminary investigation towards understanding the drug interactions in a population with long term mental health and physical health ailments. Awareness regarding the potential interactions can help avoid combinations with possible detrimental effects. The limitations of this study, in terms of sample size and quality of available data, can be overcome by conducting a planned study on a larger population. Financial Sponsorship: none Conflict of interests: none Cambridge University Press 2023-07-07 /pmc/articles/PMC10345774/ http://dx.doi.org/10.1192/bjo.2023.496 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. This does not need to be placed under each abstract, just each page is fine. |
spellingShingle | Psychopharmacology Tewari, Abhinav Pathak, Ashish Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting |
title | Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting |
title_full | Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting |
title_fullStr | Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting |
title_full_unstemmed | Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting |
title_short | Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting |
title_sort | multimorbidity and polypharmacy in psychosis: identifying potentially significant drug interactions in an old age inpatient psychiatry setting |
topic | Psychopharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345774/ http://dx.doi.org/10.1192/bjo.2023.496 |
work_keys_str_mv | AT tewariabhinav multimorbidityandpolypharmacyinpsychosisidentifyingpotentiallysignificantdruginteractionsinanoldageinpatientpsychiatrysetting AT pathakashish multimorbidityandpolypharmacyinpsychosisidentifyingpotentiallysignificantdruginteractionsinanoldageinpatientpsychiatrysetting |